Kalaris Therapeutics, Inc. (KLRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.49M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kalaris Therapeutics, Inc. (KLRS) Competitors
The companies most similar to Kalaris Therapeutics are Plus Therapeutics (PSTV), Telomir Pharmaceuticals, Inc. Common Stock (TELO) and OS Therapies (OSTX). By market cap, Kalaris Therapeutics ranks 6th of the 13 companies on this page; Oncolytics Biotech (ONCY) is the largest at $48.51M.
Peer Comparison
KLRS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics (KLRS) | $37.49M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| OS Therapies Incorporated (OSTX) | $34.87M | N/A | N/A | 0.0% | 218.0% | 0.0% | 0.00% |
| Grace Therapeutics, Inc. (GRCE) | $38.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Quince Therapeutics, Inc. (QNCX) | $32.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Gain Therapeutics Inc (GANX) | $46.31M | N/A | N/A | 0.0% | -170.5% | -100.0% | 0.00% |
| Serina Therapeutics Inc (SER) | $36.93M | N/A | 288.7x | 0.0% | -109.4% | 154.9% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| Barinthus Biotherapeutics plc (BRNS) | $30.23M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Lite Strategy, Inc. (LITS) | $25.30M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oncolytics Biotech Inc (ONCY) | $48.51M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $36.54M | N/A | 68.5x | 0.0% | -109.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Kalaris Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| OS Therapies Incorporated (OSTX) | OS Therapies Incorporated is a pioneering biopharmaceutical company committed to developing innovative treatments for unmet medical needs... | OSTX competitors |
| Grace Therapeutics, Inc. (GRCE) | Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. | GRCE competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Quince Therapeutics, Inc. (QNCX) | Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. | |
| Gain Therapeutics Inc (GANX) | Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. | GANX competitors |
| Serina Therapeutics Inc (SER) | Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology... | SER competitors |
| Instil Bio Inc. (TIL) | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| Barinthus Biotherapeutics plc (BRNS) | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system... | BRNS competitors |
| Lite Strategy, Inc. (LITS) | Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. | LITS competitors |
| Oncolytics Biotech Inc (ONCY) | Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. | ONCY competitors |
Frequently Asked Questions About KLRS
Who are Kalaris Therapeutics' main competitors?
The companies most similar to Kalaris Therapeutics include Plus Therapeutics (PSTV), Telomir Pharmaceuticals, Inc. Common Stock (TELO), OS Therapies (OSTX), Grace Therapeutics (GRCE) and ImageneBio (IMA), listed from the closest match.
Who is Kalaris Therapeutics' biggest competitor?
Oncolytics Biotech (ONCY) is the largest of the similar companies at $48.51M; Plus Therapeutics (PSTV) is the closest match by business profile, size, sector and industry.
How does KLRS stock compare with its competitors?
KLRS' net margin is 0.0% against a peer median of 0.0%.
Which of Kalaris Therapeutics' competitors pays a higher dividend?
Kalaris Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Kalaris Therapeutics bigger than its competitors?
No. Kalaris Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Oncolytics Biotech (ONCY) at $48.51M.
KLRS pages: Overview, Earnings, Forecast, Financials, Competitors